Vestcor Inc Has $1.28 Million Stake in United Therapeutics Corporation $UTHR

Vestcor Inc raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 59.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 3,056 shares of the biotechnology company’s stock after purchasing an additional 1,135 shares during the quarter. Vestcor Inc’s holdings in United Therapeutics were worth $1,281,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in UTHR. WINTON GROUP Ltd acquired a new stake in United Therapeutics during the third quarter worth about $8,849,000. Schroder Investment Management Group raised its holdings in United Therapeutics by 0.4% in the 3rd quarter. Schroder Investment Management Group now owns 30,323 shares of the biotechnology company’s stock valued at $12,866,000 after acquiring an additional 128 shares in the last quarter. Rhenman & Partners Asset Management AB bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $3,354,000. Grantham Mayo Van Otterloo & Co. LLC grew its holdings in shares of United Therapeutics by 67.6% during the 3rd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 15,068 shares of the biotechnology company’s stock worth $6,317,000 after purchasing an additional 6,079 shares in the last quarter. Finally, Orion Porfolio Solutions LLC grew its holdings in shares of United Therapeutics by 20.4% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 4,225 shares of the biotechnology company’s stock worth $1,771,000 after purchasing an additional 715 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, Director Tommy G. Thompson sold 2,000 shares of United Therapeutics stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $489.42, for a total transaction of $978,840.00. Following the completion of the transaction, the director directly owned 8,480 shares of the company’s stock, valued at $4,150,281.60. This trade represents a 19.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the completion of the transaction, the chief executive officer owned 130 shares in the company, valued at approximately $70,140.20. This trade represents a 98.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 342,947 shares of company stock worth $167,479,373 in the last three months. Company insiders own 10.30% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: NEJM publishes full Phase 3 TETON-2 results showing nebulized Tyvaso met its primary endpoint in IPF, providing clear clinical validation for an important label expansion that can drive revenue upside. TETON-2/NEJM
• Positive Sentiment: Analyst/upgrades and constructive research: several brokers have raised price targets and buy ratings recently (RBC, TD Cowen, UBS among others), supporting a higher valuation and reinforcing upside expectations. Analyst Coverage
• Positive Sentiment: Pipeline derisking commentary and a Seeking Alpha upgrade highlight ralinepag’s Phase 3 success and call out meaningful longer-term upside (base-case fair value cited materially above current levels), which can lift sentiment on growth prospects. Seeking Alpha
• Positive Sentiment: Institutional accumulation: large funds (Wellington, Norges Bank, Darwin Global, Invesco, Avoro) have recently increased positions, which supports liquidity and longer-term investor confidence. Institutional Holdings
• Neutral Sentiment: Market commentary: coverage (e.g., Zacks) notes recent outsized intraday moves and volume spikes but cautions that revised earnings estimates may limit immediate follow-through; useful for trade/timing perspective rather than fundamental change. Zacks
• Negative Sentiment: Significant insider selling: CEO Martine Rothblatt executed multiple large sales (3/6, 3/9 and 3/11 filings) totaling many thousands of shares, leaving a small residual holding; large timed sales can create short-term headline pressure even if for personal/liquidity reasons. SEC filings: 3/11 3/11 SEC, 3/9 3/9 SEC, 3/6 3/6 SEC

United Therapeutics Trading Up 1.7%

Shares of UTHR opened at $544.71 on Thursday. The stock has a market cap of $23.87 billion, a PE ratio of 19.52, a PEG ratio of 1.93 and a beta of 0.84. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $548.12. The stock has a 50 day simple moving average of $484.97 and a 200-day simple moving average of $458.01.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the previous year, the firm earned $6.19 EPS. United Therapeutics’s quarterly revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of a number of recent research reports. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada boosted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. HC Wainwright increased their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.